The Medicines and Healthcare products Regulatory Agency (MHRA) looks like it will once again be responsible for regulating drugs across the whole of the UK, in the wake of
A £1.6 billion ($1.9 billion) pot of cash that had been ringfenced for R&D spending in the UK has been returned to the Treasury, to the dismay of leading science organ
UK scientists are being denied from joining the €95 billion Horizon research funding programme as a dispute over the trade border in Northern Ireland gets increasingly acrimonious.
The MHRA has kicked off an eight-week consultation on proposals for changes to laws governing the conduct of clinical trials following the UK's departure from the EU.
Post-pandemic, post-Brexit Britain must create a regulatory framework that both defines and aligns with international standards, or risk being left behind.
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte